Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Feb 15, 2024; 16(2): 331-342
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.331
Published online Feb 15, 2024. doi: 10.4251/wjgo.v16.i2.331
Item | All patients (n= 126) | Low BMI (n= 74) | High BMI (n= 52) | P value |
General characteristics | ||||
Male | 85 (67.5) | 48 (64.9) | 37 (71.2) | 0.458 |
Age ≥ 60 yr | 54 (42.9) | 37 (50.0) | 17 (32.7) | 0.053 |
BMI, kg/m2 | 23.6 ± 3.5 | 21.2 ± 1.8 | 27.0 ± 2.3 | < 0.001 |
Weight gain ≥ 5% | 34 (27.0) | 18 (24.3) | 16 (30.8) | 0.254 |
Weight loss ≥ 5% | 17 (13.5) | 13 (17.6) | 4 (7.7) | 0.254 |
Hypertension | 50 (39.7) | 23 (31.1) | 27 (51.9) | 0.019 |
Diabetes | 20 (15.9) | 10 (13.5) | 10 (19.2) | 0.387 |
Primary colorectal tumour | ||||
Primary site, colon | 62 (49.2) | 37 (50.0) | 25 (48.1) | 0.832 |
Lymph nodal metastasis1 | 77 (68.8) | 49 (73.1) | 28 (62.2) | 0.222 |
Liver metastases | ||||
Synchronous | 83 (65.9) | 52 (70.3) | 31 (59.6) | 0.214 |
Bilobar distribution | 47 (37.3) | 26 (35.1) | 21 (40.4) | 0.549 |
Diameter of largest metastases ≥ 3.0 cm | 46 (36.5) | 24 (32.4) | 22 (42.3) | 0.257 |
Multiple metastases | 61 (48.4) | 36 (48.6) | 25 (48.1) | 0.950 |
Preoperative chemotherapy details | ||||
Oxaliplatin-based regimen | 95 (75.4) | 60 (81.1) | 35 (67.3) | 0.077 |
Bevacizumab | 45 (35.7) | 26 (35.1) | 19 (36.5) | 0.871 |
Cycles > 6 | 32 (25.4) | 18 (24.3) | 14 (26.9) | 0.741 |
Therapy delayed or dose reduced | 15 (11.9) | 9 (12.2) | 6 (11.5) | 0.915 |
Surgical details | ||||
Preoperative CEA ≥ 10 ng/mL | 52 (41.3) | 27 (36.5) | 25 (48.1) | 0.193 |
Laparoscopic | 101 (80.2) | 59 (79.7) | 42 (80.8) | 0.885 |
Simultaneous | 35 (27.8) | 16 (21.6) | 19 (36.5) | 0.066 |
Pringle manoeuver | 89 (70.6) | 51 (68.9) | 38 (73.1) | 0.614 |
Postoperative details | ||||
Morbidity (Dindo-Clavien II-V) | 29 (23.0) | 17 (23.0) | 12 (23.1) | 0.989 |
Length of hospital stay (median, Q1-Q3) | 8.0 (6.0-10.8) | 8.0 (6-10) | 8.0 (6-11.0) | 0.539 |
Pathology details | ||||
Complete tumour response | 27 (21.4) | 22 (29.7) | 5 (9.6) | 0.007 |
Steatosis | 56 (44.4) | 30 (40.5) | 26 (50.0) | 0.293 |
Sinusoidal dilatation | 103 (82.4) | 62 (84.9) | 41 (78.8) | 0.379 |
Severe steatosis (grade 2-3) | 17 (13.5) | 6 (8.1) | 11 (21.2) | 0.035 |
Severe sinusoidal dilatation (grade 2-3) | 30 (23.8) | 19 (25.7) | 11 (21.2) | 0.557 |
Factor | n (%) | Complete tumour response (TRG1-2) | |
OR (95%CI) | P value | ||
Male | 85 (67.5) | 0.42 (0.18-1.02) | 0.054 |
Age ≥ 60 yr | 54 (42.9) | 0.90 (0.38-2.13) | 0.802 |
Low BMI | 74 (58.7) | 3.98 (1.39-11.34) | 0.010 |
Weight gain ≥ 5% | 34 (27.0) | 0.68 (0.24-1.90) | 0.460 |
Weight loss ≥ 5% | 17 (13.5) | 0.68 (0.18-2.63) | 0.575 |
Hypertension | 50 (39.7) | 0.57 (0.23-1.43) | 0.232 |
Diabetes | 20 (15.9) | 0.60 (0.16-2.23) | 0.449 |
Primary site, colon | 62 (49.2) | 0.78 (0.33-1.84) | 0.577 |
Lymph nodal metastasis1 | 77 (68.8) | 0.88 (0.35-2.22) | 0.789 |
Synchronous | 83 (65.9) | 2.09 (0.77-5.65) | 0.147 |
Bilobar distribution | 47 (37.3) | 1.78 (0.75-4.20) | 0.192 |
Diameter ≥ 3.0 cm | 46 (36.5) | 1.53 (0.64-3.63) | 0.336 |
Multiple metastases | 61 (48.4) | 1.19 (0.51-2.79) | 0.687 |
Oxaliplatin-based regimen | 95 (75.4) | 3.15 (0.88-11.32) | 0.078 |
Bevacizumab | 45 (35.7) | 2.88 (1.20-6.87) | 0.018 |
Cycles > 6 | 32 (25.4) | 0.80 (0.29-2.21) | 0.669 |
Preoperative CEA < 10 ng/mL | 74 (58.7) | 3.98 (1.39-11.34) | 0.010 |
Steatosis | 73 (57.9) | 1.07 (0.45-2.55) | 0.875 |
Sinusoidal dilatation | 103 (82.4) | 0.64 (0.22-1.85) | 0.412 |
Severe steatosis (grade 2-3) | 17 (13.5) | 1.65 (0.53-5.17) | 0.392 |
Severe sinusoidal dilatation (grade 2-3) | 30 (23.8) | 0.20 (0.05-0.91) | 0.038 |
- Citation: Song HC, Zhou HC, Gu P, Bao B, Sun Q, Mei TM, Cui W, Yao K, Yao HZ, Zhang SY, Wang YS, Song RP, Wang JZ. Tumour response following preoperative chemotherapy is affected by body mass index in patients with colorectal liver metastases. World J Gastrointest Oncol 2024; 16(2): 331-342
- URL: https://www.wjgnet.com/1948-5204/full/v16/i2/331.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i2.331